ArticleScientific reports2026
FcIgG-GE11-Melittin as a novel EGFR targeted peptibody with potent cytotoxic activity against cancer cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The overexpression of epidermal growth factor receptor (EGFR) in various cancer types makes it an attractive target for therapeutic intervention. In this study, we designed a novel peptibody, FcIgG-GE11-Melittin, by fusing Melittin, a cytotoxic peptide from bee venom, to an EGFR-targeting peptibody (FcIgG-GE11). The FcIgG-GE11 component ensures specific binding to EGFR-overexpressing cancer cells, while Melittin induces cell death through its lytic activity. We evaluated the efficacy of FcIgG-GE11-Melittin in vitro using EGFR-overexpressing cancer cell lines. Our results demonstrate that FcIgG-GE11-Melittin selectively targets and kills EGFR-positive cancer cells while sparing normal cells. These findings highlight the potential of FcIgG-GE11-Melittin as a targeted therapeutic agent for EGFR-overexpressing cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.